|Bid||37.07 x 1300|
|Ask||37.24 x 900|
|Day's Range||35.89 - 37.64|
|52 Week Range||19.23 - 49.24|
|Beta (5Y Monthly)||1.26|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 02, 2023 - May 08, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||63.38|
Today is shaping up negative for Morphic Holding, Inc. ( NASDAQ:MORF ) shareholders, with the analysts delivering a...
WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate a panel discussion focused on new approached to treat gastroenterological diseases and a corporate fireside chat at the TD Cowen 43rd Annual Health Care Conference. Presentation Information GI/Microbiome Panel Discussion9:10 AM E
Morphic Holding ( NASDAQ:MORF ) Full Year 2022 Results Key Financial Results Revenue: US$70.8m (up 258% from FY 2021...